Clinical trialObsCompleted
Pancreatic Surgery in Elderly Patients
Postoperative and Long-term Survival in Relation to Life-expectancy After Pancreatic Surgery in Elderly Patients
- Outcome
- Finished, no results posted
- Phase
- Obs
- Status
- Completed
- Study type
- Observational
- Start
- 1 January 2010
- Expected end
- 31 December 2019
- Enrollment
- 1,556 participants
- Sites
- 0
- Primary outcomes
- postoperative mortality; long time survival in patients operated for pancreatic cancer
- Sponsor
- Other
- Results posted
- No
- Last update
- 30 November 2023
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 6
- BackgroundFOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. DOI 10.1056/nejmoa1809775↗
- BackgroundResection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. DOI 10.1136/gutjnl-2017-314828↗
- BackgroundComparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic c… DOI 10.1016/s0140-6736(16)32409-6↗
- BackgroundElderly Patients Strongly Benefit from Centralization of Pancreatic Cancer Surgery: A Population-Based Study. DOI 10.1245/s10434-016-5089-3↗
- BackgroundIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. DOI 10.1056/nejmoa1304369↗
- BackgroundFOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. DOI 10.1056/nejmoa1011923↗